

# Press Release

Skanska Signs Another Lease at 150 Second Street in Cambridge, MA  
*Gene therapy biotech company, bluebird bio, Inc., inks multi-year deal*

**Cambridge, MA** (July 16, 2013) – [Skanska USA Commercial Development Inc.](#) announced today that it has secured another lease at 150 Second Street in Cambridge's Kendall Square with [bluebird bio](#), a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. bluebird bio will occupy 43,586 square feet beginning in January 2014.

"We are excited to welcome another innovative company to our building that represents the pioneering culture and personality unique to Kendall Square," said Shawn Hurley, executive vice president for Skanska USA Commercial Development in Boston. "The neighborhood continues to flourish and attract leading edge companies, like bluebird bio."

bluebird bio joins anchor tenant Foundation Medicine Inc. at 150 Second Street. Foundation Medicine is a molecular information company that uses genomic analysis to help doctors identify targeted cancer treatments that might be best for each patient. Foundation Medicine Inc. is scheduled to start a 61,591 square foot lease this September which, with bluebird bio, brings the building to 85 percent leased.

Jones Lang LaSalle represented Skanska USA Commercial Development and Colliers International represented bluebird bio.

150 Second Street, which was completed in December 2012, is a LEED® Gold pre-certified lab and office building representing Skanska's first commercial development investment in Cambridge. Skanska acquired the property in November of 2010 and self-financed the development costs for the three-story Class A project.

Skanska USA Commercial Development, which launched in late 2008, is focused on the development of Class A commercial projects and is committed to delivering sustainable buildings. In addition to Boston, Skanska also has commercial development groups in Washington D.C., Houston and Seattle.

**For further information please contact:**

Jessica Murray, 404.946.7468, [jessica.murray@skanska.com](mailto:jessica.murray@skanska.com)  
Lauren Michaels, 617.933.5014, [lmichaels@solomonmccown.com](mailto:lmichaels@solomonmccown.com)

**This and previous releases can also be found at [www.skanska.com](http://www.skanska.com)**

*Skanska USA is one of the largest, most financially sound construction and development networks in the country, serving a broad range of industries including healthcare, education, sports, data centers, government, aviation, transportation, power, energy, water/wastewater and commercial. Headquartered in New York with 39 offices across the country, Skanska USA employs more than 8,300 employees committed to sustainable construction and development and an injury-free workplace. Skanska USA Building, which specializes in building construction, and Skanska USA Civil, which focuses on civil infrastructure, generated \$5.8 billion in revenue in 2012, representing 30 percent of Skanska's global construction revenue. Development units Skanska USA Commercial Development, which invests in and develops office and multi-family projects in select U.S. markets, and Skanska Infrastructure Development North America, which develops public-private partnerships, are both leaders in their selected markets. Global revenue of parent company Skanska AB, headquartered in Stockholm and listed on the Stockholm Stock Exchange, totaled \$19.5 billion in 2012.*

***About bluebird bio, Inc.***

*bluebird bio is developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development, one for childhood cerebral adrenoleukodystrophy (CCALD) and one for beta-thalassemia major/severe sickle cell disease, and an early stage oncology program in partnership with Celgene Corporation. Led by a management team with extensive industry experience, bluebird bio is a publicly traded company (NASDAQ: BLUE) backed by top-tier life sciences investors. Its operations are located in Cambridge, Mass., San Francisco and Paris, France. For more information, please visit [www.bluebirdbio.com](http://www.bluebirdbio.com).*

###